Tags

Type your tag names separated by a space and hit enter

A novel treatment target for Parkinson's disease.
J Neurol Sci. 2014 Dec 15; 347(1-2):34-8.JN

Abstract

We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A.

Authors+Show Affiliations

Department of Physical Therapy, Georgia Regents University, Augusta, GA, USA. Electronic address: cwakade@gru.edu.Department of Physical Therapy, Georgia Regents University, Augusta, GA, USA. Electronic address: rchong@gru.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25455298

Citation

Wakade, Chandramohan, and Raymond Chong. "A Novel Treatment Target for Parkinson's Disease." Journal of the Neurological Sciences, vol. 347, no. 1-2, 2014, pp. 34-8.
Wakade C, Chong R. A novel treatment target for Parkinson's disease. J Neurol Sci. 2014;347(1-2):34-8.
Wakade, C., & Chong, R. (2014). A novel treatment target for Parkinson's disease. Journal of the Neurological Sciences, 347(1-2), 34-8. https://doi.org/10.1016/j.jns.2014.10.024
Wakade C, Chong R. A Novel Treatment Target for Parkinson's Disease. J Neurol Sci. 2014 Dec 15;347(1-2):34-8. PubMed PMID: 25455298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A novel treatment target for Parkinson's disease. AU - Wakade,Chandramohan, AU - Chong,Raymond, Y1 - 2014/10/23/ PY - 2014/02/28/received PY - 2014/09/19/revised PY - 2014/10/14/accepted PY - 2014/12/3/entrez PY - 2014/12/3/pubmed PY - 2015/8/8/medline KW - GPR109A KW - HCAR2 KW - HM74a KW - Inflammation KW - Niacin KW - Niacinamide SP - 34 EP - 8 JF - Journal of the neurological sciences JO - J Neurol Sci VL - 347 IS - 1-2 N2 - We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists are known to exert anti-inflammatory actions in the skin, gut and retina. However these roles are neither anticipated nor established in the CNS. For the first time here we propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover we predict that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR109A. SN - 1878-5883 UR - https://www.unboundmedicine.com/medline/citation/25455298/A_novel_treatment_target_for_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(14)00677-7 DB - PRIME DP - Unbound Medicine ER -